Adjuvant Proton Beam Therapy in the Management of Thymoma: A Dosimetric Comparison and Acute Toxicities

Rahul R. Parikh, Ryan Rhome, Eugen Hug, Henry Tsai, Oren Cahlon, Brian Chon, Anuj Goenka

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


We evaluated the treatment planning differences between adjuvant proton therapy and intensity modulated radiotherapy for patients with resected thymoma. We also report the early clinical outcomes and potential toxicities in patients undergoing proton therapy. Adjuvant proton therapy was associated with superior dosimetric outcome and was clinically well tolerated. Background We evaluated the dosimetric differences between proton beam therapy (PBT) and intensity modulated radiation therapy (IMRT) for resected thymoma. We simultaneously report our early clinical experience with PBT in this cohort. Patients and Methods We identified 4 patients with thymoma or thymic carcinoma treated at our center from 2012 to 2014 who completed adjuvant PBT to a median dose of 57.0 cobalt Gy equivalents (CGE; range, 50.4-66.6 CGE) after definitive resection. Adjuvant radiation was indicated for positive (n = 3) or close margin (n = 1). Median age was 45 (range, 32-70) years. Stages included II (n = 2), III (n = 1), and IVA (n = 1). Analogous IMRT plans were generated for each patient for comparison, and preset dosimetric endpoints were evaluated. Early toxicities were assessed according to retrospective chart review. Results Compared with IMRT, PBT was associated with lower mean doses to the lung (4.6 vs. 8.1 Gy; P = .02), esophagus (5.4 vs. 20.6 Gy; P = .003), and heart (6.0 vs. 10.4 Gy; P = .007). Percentages of lung, esophagus, and heart receiving radiation were consistently lower in the PBT plans over a wide range of radiation doses. There was no difference in mean breast dose (2.68 vs. 3.01 Gy; P = .37). Of the 4 patients treated with PBT, 3 patients experienced Grade 1 radiation dermatitis, and 1 patient experienced Grade 2 dermatitis, which resolved after treatment. With a median follow-up of 5.5 months, there were no additional Grade ≥ 2 acute or subacute toxicities, including radiation pneumonitis. Conclusion PBT is clinically well tolerated after surgical resection of thymoma, and is associated with a significant reduction in dose to critical structures without compromising coverage of the target volume. Prospective evaluation and longer follow-up is needed to assess clinical outcomes and late toxicities.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalClinical Lung Cancer
Issue number5
StatePublished - Sep 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


  • Adjuvant radiation
  • IMRT
  • Mediastinum
  • Proton therapy
  • Radiation therapy
  • Thymoma


Dive into the research topics of 'Adjuvant Proton Beam Therapy in the Management of Thymoma: A Dosimetric Comparison and Acute Toxicities'. Together they form a unique fingerprint.

Cite this